CA2979302A1 - Substituted quinoxaline derivatives - Google Patents
Substituted quinoxaline derivatives Download PDFInfo
- Publication number
- CA2979302A1 CA2979302A1 CA2979302A CA2979302A CA2979302A1 CA 2979302 A1 CA2979302 A1 CA 2979302A1 CA 2979302 A CA2979302 A CA 2979302A CA 2979302 A CA2979302 A CA 2979302A CA 2979302 A1 CA2979302 A1 CA 2979302A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- quinoxalin
- indol
- amine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001451.2 | 2015-05-13 | ||
| EP15460017.5 | 2015-05-13 | ||
| EP15001451 | 2015-05-13 | ||
| EP15460017 | 2015-05-14 | ||
| PCT/EP2016/000783 WO2016180536A1 (en) | 2015-05-13 | 2016-05-12 | Substituted quinoxaline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2979302A1 true CA2979302A1 (en) | 2016-11-17 |
Family
ID=56081443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2979302A Abandoned CA2979302A1 (en) | 2015-05-13 | 2016-05-12 | Substituted quinoxaline derivatives |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180148429A1 (enExample) |
| EP (1) | EP3294729A1 (enExample) |
| JP (1) | JP2018515612A (enExample) |
| CN (1) | CN107635986A (enExample) |
| AU (1) | AU2016261031A1 (enExample) |
| CA (1) | CA2979302A1 (enExample) |
| IL (1) | IL254870A0 (enExample) |
| TW (1) | TW201713641A (enExample) |
| WO (1) | WO2016180536A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2823180T3 (es) * | 2016-07-14 | 2021-05-06 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos con heteroarilo |
| EP3538518A1 (en) * | 2016-11-08 | 2019-09-18 | Merck Patent GmbH | Substituted quinoxaline derivatives as inhibitors of pfkfb |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| US20200275661A1 (en) * | 2017-09-26 | 2020-09-03 | Nippon Soda Co., Ltd. | Quinoline compound, and agricultural and horticultural fungicide |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| DK3768684T3 (da) | 2018-03-22 | 2023-04-24 | Hoffmann La Roche | Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere |
| JP7478142B2 (ja) | 2018-06-07 | 2024-05-02 | ディスアーム セラピューティクス, インコーポレイテッド | Sarm1阻害剤 |
| MY210507A (en) | 2018-08-13 | 2025-09-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| JP2022508751A (ja) * | 2018-10-15 | 2022-01-19 | ゲロ ディスカバリー リミテッド ライアビリティ カンパニー | Pfkfb3阻害剤とその使用 |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| CN114072405A (zh) | 2019-07-03 | 2022-02-18 | 豪夫迈·罗氏有限公司 | 杂环单酰基甘油脂肪酶(magl)抑制剂 |
| KR20220034104A (ko) | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 신규 헤테로고리 화합물 |
| CN121045142A (zh) * | 2019-08-06 | 2025-12-02 | 北卡罗来纳查佩尔山大学 | Rna靶向配体、其组合物以及其制备和使用方法 |
| CN110698418B (zh) * | 2019-09-11 | 2022-07-01 | 广西师范大学 | 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用 |
| PH12022550339A1 (en) | 2019-09-12 | 2023-03-13 | Hoffmann La Roche | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| MX2022003023A (es) | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
| CN115515959B (zh) * | 2020-05-08 | 2026-03-31 | 默克专利股份公司 | 用作tead结合剂的三环杂环 |
| EP4185564A1 (en) * | 2020-07-23 | 2023-05-31 | Merck Patent GmbH | Tricyclic heterocycles |
| WO2022043284A1 (en) | 2020-08-26 | 2022-03-03 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as magl inhibitors |
| PE20231372A1 (es) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | Compuestos heterociclicos |
| WO2022115521A1 (en) | 2020-11-25 | 2022-06-02 | Servier Pharmaceuticals, Llc | (heteo)aryl substituted pyrrolo-, pyrazolo- and triazolopyridazine derivates as mat2a inhibitors |
| EP4337653A4 (en) * | 2021-06-02 | 2025-07-23 | Univ North Carolina Chapel Hill | RNA TARGETING LIGANDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME |
| WO2023247670A1 (en) | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| WO2025084787A1 (ko) * | 2023-10-17 | 2025-04-24 | 가천대학교 산학협력단 | 신규 퀴녹살린 화합물, 이의 제조방법 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5633218A (en) * | 1995-05-24 | 1997-05-27 | E. I. Du Pont De Nemours And Company | Herbicidal benzodioxoles and benzodioxanes |
| US20140128392A1 (en) * | 2009-03-19 | 2014-05-08 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US9403769B2 (en) * | 2010-02-22 | 2016-08-02 | Advanced Cancer Therapeutics, Llc | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics |
| TW201311149A (zh) * | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| WO2013148228A1 (en) * | 2012-03-29 | 2013-10-03 | Advanced Cancer Therapeutics, Llc | Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic |
-
2016
- 2016-05-12 US US15/572,470 patent/US20180148429A1/en not_active Abandoned
- 2016-05-12 CA CA2979302A patent/CA2979302A1/en not_active Abandoned
- 2016-05-12 JP JP2018511333A patent/JP2018515612A/ja active Pending
- 2016-05-12 TW TW105114781A patent/TW201713641A/zh unknown
- 2016-05-12 WO PCT/EP2016/000783 patent/WO2016180536A1/en not_active Ceased
- 2016-05-12 CN CN201680027578.3A patent/CN107635986A/zh active Pending
- 2016-05-12 AU AU2016261031A patent/AU2016261031A1/en not_active Abandoned
- 2016-05-12 EP EP16725031.5A patent/EP3294729A1/en not_active Withdrawn
-
2017
- 2017-10-03 IL IL254870A patent/IL254870A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018515612A (ja) | 2018-06-14 |
| WO2016180536A1 (en) | 2016-11-17 |
| AU2016261031A1 (en) | 2017-10-05 |
| EP3294729A1 (en) | 2018-03-21 |
| US20180148429A1 (en) | 2018-05-31 |
| TW201713641A (zh) | 2017-04-16 |
| CN107635986A (zh) | 2018-01-26 |
| IL254870A0 (en) | 2017-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016261031A1 (en) | Substituted quinoxaline derivatives | |
| AU2019334264B2 (en) | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | |
| RU2722363C2 (ru) | Замещенное производное 2н-пиразола | |
| ES2900184T3 (es) | Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2 | |
| CN109890819A (zh) | 作为免疫调节剂的杂环化合物 | |
| WO2016041618A1 (en) | Substituted indazoles and related heterocycles | |
| WO2017003995A1 (en) | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | |
| EP3283475A1 (en) | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives | |
| CA3025220A1 (en) | Tricyclic heterocylic derivatives | |
| AU2021312027A1 (en) | Tricyclic heterocycles | |
| WO2016180537A1 (en) | Substituted quinoxaline derivatives | |
| BR112014024489B1 (pt) | derivados de tienopirimidina, processos para a preparação dos mesmos, medicamento e composição farmacêutica | |
| AU2021268094A1 (en) | Tricyclic heterocycles useful as TEAD binders | |
| US20240317753A9 (en) | Tricyclic heterocycles | |
| CN121752567A (zh) | 用于抑制wee1 a激酶方法中的吡唑并嘧啶酮化合物 | |
| EP4423091A1 (en) | Tricyclic heterocycles | |
| EP4121423B1 (en) | Tetrazole derivatives | |
| CA3259052A1 (en) | HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS. | |
| CA3218932A1 (en) | 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer | |
| JP2020537661A (ja) | ピリミジンTBK/IKKεインヒビター化合物およびそれらの使用 | |
| WO2025113625A1 (zh) | 作为pkmyt1抑制剂的杂芳环和杂双环化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220301 |